Gabelli Funds LLC lowered its position in Astrazeneca Plc (NYSE:AZN – Free Report) by 12.9% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 63,000 shares of the company’s stock after selling 9,300 shares during the period. Gabelli Funds LLC’s holdings in Astrazeneca were worth $11,056,000 as of its most recent SEC filing.
A number of other institutional investors also recently bought and sold shares of the stock. Bank of America Corp DE boosted its stake in Astrazeneca by 4.7% in the 3rd quarter. Bank of America Corp DE now owns 32,633,139 shares of the company’s stock worth $2,503,614,000 after purchasing an additional 1,461,786 shares in the last quarter. Fisher Asset Management LLC lifted its stake in shares of Astrazeneca by 2.3% in the 3rd quarter. Fisher Asset Management LLC now owns 21,162,724 shares of the company’s stock valued at $1,623,604,000 after purchasing an additional 466,745 shares during the period. Dimensional Fund Advisors LP lifted its stake in shares of Astrazeneca by 9.4% in the 3rd quarter. Dimensional Fund Advisors LP now owns 6,805,896 shares of the company’s stock valued at $521,517,000 after purchasing an additional 582,183 shares during the period. Holocene Advisors LP lifted its stake in shares of Astrazeneca by 41.8% in the 3rd quarter. Holocene Advisors LP now owns 6,129,194 shares of the company’s stock valued at $470,232,000 after purchasing an additional 1,807,565 shares during the period. Finally, Ameriprise Financial Inc. lifted its stake in shares of Astrazeneca by 13.1% in the 3rd quarter. Ameriprise Financial Inc. now owns 5,707,561 shares of the company’s stock valued at $438,342,000 after purchasing an additional 660,569 shares during the period. 20.35% of the stock is currently owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
AZN has been the subject of a number of research analyst reports. Sanford C. Bernstein restated a “buy” rating on shares of Astrazeneca in a research report on Monday, May 4th. Citigroup began coverage on shares of Astrazeneca in a report on Tuesday, January 27th. They issued a “buy” rating for the company. Weiss Ratings started coverage on shares of Astrazeneca in a report on Wednesday, March 11th. They issued a “buy (b)” rating for the company. JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of Astrazeneca in a research note on Thursday, May 14th. Finally, Deutsche Bank Aktiengesellschaft reissued a “sell” rating on shares of Astrazeneca in a research report on Thursday, April 30th. Twelve analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $205.33.
Key Astrazeneca News
Here are the key news stories impacting Astrazeneca this week:
- Positive Sentiment: AstraZeneca and Daiichi Sankyo won FDA approval for Enhertu in two additional early-stage HER2-positive breast cancer settings, expanding the drug’s addressable market and strengthening the company’s oncology pipeline. AZN, Daiichi’s Enhertu Gets FDA Nod for Two New Breast Cancer Settings
- Positive Sentiment: The FDA also approved Baxfendy (baxdrostat), AstraZeneca’s first-in-class hypertension drug, which could become a meaningful new growth driver in a large cardiovascular market and may support expectations for multibillion-dollar peak sales. AstraZeneca’s blood pressure drug wins U.S. approval
- Neutral Sentiment: Some commentary on the FDA wins raised questions about valuation and the pace of long-term growth, suggesting investors may balance the near-term enthusiasm against execution and pricing concerns. AstraZeneca’s New FDA Wins Raise Questions On Growth And Valuation
- Neutral Sentiment: Erste Group Bank slightly lowered its FY2026 EPS estimate for AstraZeneca to $10.17 from $10.25, though that remains close to the consensus of $10.26 and does not materially change the earnings outlook.
Astrazeneca Trading Up 0.4%
NYSE:AZN opened at $184.69 on Wednesday. The company has a market capitalization of $286.44 billion, a PE ratio of 27.73, a price-to-earnings-growth ratio of 1.51 and a beta of 0.26. The company has a quick ratio of 0.71, a current ratio of 0.91 and a debt-to-equity ratio of 0.52. Astrazeneca Plc has a 52-week low of $137.23 and a 52-week high of $212.71. The stock has a fifty day simple moving average of $191.97 and a 200-day simple moving average of $182.43.
Astrazeneca (NYSE:AZN – Get Free Report) last announced its earnings results on Wednesday, April 29th. The company reported $2.58 earnings per share for the quarter, beating the consensus estimate of $2.52 by $0.06. Astrazeneca had a net margin of 17.19% and a return on equity of 30.86%. The firm had revenue of $15.29 billion during the quarter, compared to the consensus estimate of $14.93 billion. On average, equities research analysts expect that Astrazeneca Plc will post 10.25 earnings per share for the current fiscal year.
Astrazeneca Profile
AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.
The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.
Featured Articles
- Five stocks we like better than Astrazeneca
- HIVE Weaponizes Power for an AI Pivot
- A Deep Dive Into NVIDIA’s Latest Portfolio Moves
- Brady Corp Wires Up a Massive AI-Powered Breakout
- Why Home Depot’s Sell-Off Could Become a Huge Opportunity
Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Astrazeneca Plc (NYSE:AZN – Free Report).
Receive News & Ratings for Astrazeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca and related companies with MarketBeat.com's FREE daily email newsletter.
